Tobias Holderried

17PUBLICATIONS
185CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 18, 2026
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

|Jun 12, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|Apr 09, 2025
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

|Dec 09, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Elias K Mai, Uta Bertsch, Ema Pozek

|Dec 05, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Maximilian Merz, Danai Dima, Hamza Hashmi

Pageof 3

Frequent Collaborators

4 joint publications

Friedrich Stölzel

3 joint publications

Vladan Vucinic

3 joint publications

Olaf Penack

3 joint publications

Elias K Mai